Pelthos Therapeutics Targets Pediatric Unmet Needs With Specialty Pharma Commercialization Model
SHERIDAN, WYOMING - April 14, 2026 - Pelthos Therapeutics, Inc. has positioned itself as a specialty bio-pharmaceutical organization focused on commercializing therapeutic products for patients carrying unmet treatment burdens, with Molluscum Contagiosum identified as a primary target indication. The company's stated mission centers on bringing what it describes as innovative, safe, and efficacious therapies to patient populations where current treatment options remain inadequate. Molluscum Contagiosum - a common, contagious skin infection predominantly affecting children under 14 - represents the company's disclosed clinical focus area. Pelthos frames its operational model around expert-led commercialization rather than early-stage drug discovery.